Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hansa Biopharma AB (CHIX:HNSAs) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Hansa Biopharma AB's Enterprise Value for the quarter that ended in Jun. 2026 was kr3,038.2 Mil.
Hansa Biopharma AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-578.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB EV-to-EBIT Related Terms
Hansa Biopharma AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:HNSAS vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's EV-to-EBIT falls into.
Hansa Biopharma AB's current Enterprise Value is kr4,518.2 Mil.
Hansa Biopharma AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-578.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (CHIX:HNSAS) has a EV-to-EBIT of -7.81 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hansa Biopharma AB and its competitors. According to the industry distribution chart, Hansa Biopharma AB ranks #999999 out of 372 companies in the Biotechnology industry.
Is Hansa Biopharma AB's EV-to-EBIT too high?
Hansa Biopharma AB's current EV-to-EBIT is -7.81. Based on the distribution chart, Hansa Biopharma AB ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hansa Biopharma AB has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hansa Biopharma AB ranks #999999 out of 372 companies for EV-to-EBIT. This places Hansa Biopharma AB in the lower half of its industry. The industry median EV-to-EBIT is 15.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.09, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hansa Biopharma AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansa Biopharma AB's current EV-to-EBIT is -7.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Hansa Biopharma AB (CHIX:HNSAS) has a current EV-to-EBIT of -7.81. The stock's GF Value™ is kr14.00, compared to a current price of kr25.64 — trading 83.1% above its estimated fair value. The current EV-to-EBIT is -7.81. Hansa Biopharma AB's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Hansa Biopharma AB (CHIX:HNSAS), the current EV-to-EBIT is -7.81 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (CHIX:HNSAS) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr25.64 is trading 83.1% above its estimated GF Value™ of kr14.00.
Key valuation signals for CHIX:HNSAS:
EV-to-EBIT: -7.81
GF Value™: kr14.00 vs. price of kr25.64 (83.1% above fair value)
No single metric tells the full story. See the CHIX:HNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
45GF Score
Get the complete analysis for CHIX:HNSAS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:HNSAS has been successfully added to your 
